|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI.
|
28425039 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients presenting to the Alfred Hospital, a tertiary referral hospital, between 1 January 2010 and 31 December 2015 undergoing PCI for STEMI were identified.
|
28797607 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although recent randomized controlled clinical trials (notably TASTE [Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia] and TOTAL [Trial of Routine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI]) do not supply evidence supporting the routine use of TA in patients with ST-segment-elevation myocardial infarction, manual TA remains a therapeutic option for interventional cardiologists when treating patients with substantial thrombus burden during PPCI.
|
29042400 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
|
28230176 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background We hypothesized that female sex is a treatment effect modifier of blood flow and related 30-day mortality after primary percutaneous coronary intervention ( PCI ) for ST -segment-elevation myocardial infarction and that the magnitude of the effect on outcomes differs depending on delay to hospital presentation.
|
30764687 |
2019 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in heme-metabolism were characterized in a second STEMI-group by a dual proteomic approach analyzing in-vivo aspirated coronary thrombi at PCI (N=24) and the associated peripheral-blood changes (N=10).
|
28837209 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined LVEDP/LVEF assessment was useful in predicting MACE after successful PCI for STEMI patients and could facilitate risk stratification, as it predicts LV remodeling.
|
29143103 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consecutive patients from the Melbourne Interventional Group registry (2005-2014) who presented with STEMI and underwent primary PCI were included.
|
28963757 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
|
24952855 |
2014 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daily rIC starting on day 3 and continued for 4 weeks following successful P-PCI for STEMI did not improve LVEF as assessed by CMR after 4 months when compared with a matched control group.
|
29748420 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite primary PCI being the well-established therapy, there are rooms for further research to optimize STEMI outcomes.
|
27846459 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Door-to-balloon (DTB) time ≤90 min is an important quality indicator in the management of ST-elevation myocardial infarction (STEMI), but a considerable number of patients still do not meet this goal, particularly in countries outside the USA and Europe.Methods and Results:We analyzed 2,428 STEMI patients who underwent primary PCI ≤12 h of symptom onset who were registered in an ongoing prospective multicenter database (JCD-KiCS registry), between 2008 and 2013.
|
28228609 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
During hospitalization, Patients in prior BBs group were more likely to develop decompensated heart failure (9.9% vs. 3.6%, P<0.001), less likely to have STEMI (33.9% vs. 54.4%, P<0.001), and subsequently less PCI (73.2% vs. 81.3%, P=0.002), but higher inpatient mortality (8.8% vs. 4.8%, P=0.009).
|
28747039 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the same time period, eight consecutive patients with large anterior STEMI who received primary PCI but not HT were included as control group.
|
28087172 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of Chinese national holidays and weekends versus weekday admission on clinical outcomes in patients with STEMI undergoing primary PCI.
|
29238361 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
|
28844990 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emergent or urgent CABG for treatment of acute coronary complications following PCI is feasible and has acceptable clinical results that worsen in the presence of STEMI, cardiogenic shock, or resuscitation.
|
28457342 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
EMR on admission was independently correlated with 1-month and long-term all-cause mortality in STEMI patients undergoing P-PCI, suggesting EMR as a potential simple, useful, and inexpensive index for risk stratification of STEMI patients.
|
30416794 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fewer diabetic patients met first medical contact to PCI time for STEMI (44% vs 52%).
|
28454811 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
From 2007 to 2014, 1,525 consecutive patients (79% men, mean age 61 years) who underwent primary percutaneous coronary intervention for STEMI in the INTERSTELLAR (Incheon-Bucheon Cohort of Patients Undergoing Primary PCI for Acute ST-Elevation Myocardial Infarction) cohort were analyzed retrospectively.
|
28214004 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From 434,172 low-risk, uncomplicated ACS patients eligible for early discharge (STEMI 35%, UA/NSTEMI 65%) from the Premier database, we identified ACS care pathways, by stratifying low-risk, uncomplicated STEMI and UA/NSTEMI patients by access site for PCI (trans-radial intervention [TRI] vs transfemoral intervention [TFI]) and by length of stay (LOS).
|
31812224 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, STEMI (OR 1.61; CI 1.52-1.71), performed PCI (OR 2.65; CI 2.42-2.90) and Killip class >2 (OR 1.58; CI 1.36-1.84) favoured referral for CR, while age > 65 years, previous myocardial infarction, cerebrovascular disease or peripheral artery disease had a negative impact on referral for CR.
|
29657032 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immediate Thrombolysis Followed by PCI for Left-Main Stem STEMI if Presenting Out of Hours: Should We Go "Back to the Future"?
|
29086731 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of diagnostic ECG-to-wire delay in STEMI patients treated with primary PCI: a DANAMI-3 substudy.
|
29278352 |
2018 |